<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630562</url>
  </required_header>
  <id_info>
    <org_study_id>17-PP-18</org_study_id>
    <nct_id>NCT03630562</nct_id>
  </id_info>
  <brief_title>Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration</brief_title>
  <acronym>TARMAC-1</acronym>
  <official_title>Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-VEGF intravitreal injections are the treatment of choice in age-related macular
      degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these
      therapies. It is still not possible to foresee the patient's response to anti-VEGF
      injections. A poor response may be related to an activation of alternative pro-angiogenic
      pathways with over expression of many other pro-angiogenic cytokines.

      The primary goal of this study is to measure the aqueous humor concentration of
      pro-angiogenic cytokines in AMD patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months</measure>
    <time_frame>At Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose of VEGF in the aqueous humor of patients with exudative AMD</measure>
    <time_frame>At Day 0, Month 1, Month 2, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of pro inflammatory cytokines in the aqueous humor of patients with exudative AMD</measure>
    <time_frame>At Day 0, Month 1, Month 2, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of visual acuity with Snellen chart</measure>
    <time_frame>At Day 0, Month 1, Month 2, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of visual acuity with ETDRS visual acuity chart</measure>
    <time_frame>At Day 0, Month 1, Month 2, Month 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Patients with exudative AMD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aqueous humor samples collection</intervention_name>
    <description>In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.</description>
    <arm_group_label>Patients with exudative AMD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Diagnosis of exudative age-related macular degeneration requiring intravitreal
             anti-VEGF treatment.

          -  Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly
             more than 3 months

          -  Signature of informed consent

          -  Affiliation to the French social security system

        Exclusion Criteria:

          -  Pregnant or nursing patient (a urinary pregnancy test will be performed)

          -  Systemic treatment with anti-VEGF

          -  Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated
             eye.

          -  Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as
             diabetic retinopathy, venous occlusions, intermediate and posterior uveitis.

          -  Diabetes Mellitus

          -  High Myopia

          -  Simultaneous participation in another clinical research protocol in exudative AMD

          -  Person under guardianship, under curatorship, deprived of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Stéphanie BAILLIF, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof. Stéphanie BAILLIF, MD, PhD</last_name>
    <phone>+33 (0)4.92.03.80.25</phone>
    <email>baillif.s@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pasteur 2 - Service d'Ophtalmologie</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof. Stéphanie BAILLIF, MD, PhD</last_name>
      <phone>+33 (0)4.92.03.80.25</phone>
      <email>baillif.s@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

